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ARTICLE
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Cutaneous melanoma represents the most fatal skin cancer due to its high metastatic
capacity. According to the “phenotype switching” model, the aggressive nature of melanoma
cells results from their intrinsic potential to dynamically switch from a high-proliferative/low-
invasive to a low-proliferative/high-invasive state. Here we identify the low afﬁnity neuro-
trophin receptor CD271 as a key effector of phenotype switching in melanoma. CD271 plays a
dual role in this process by decreasing proliferation, while simultaneously promoting inva-
siveness. Dynamic modiﬁcation of CD271 expression allows tumor cells to grow at low levels
of CD271, to reduce growth and invade when CD271 expression is high, and to re-expand at a
distant site upon decrease of CD271 expression. Mechanistically, the cleaved intracellular
domain of CD271 controls proliferation, while the interaction of CD271 with the neurotrophin
receptor Trk-A modulates cell adhesiveness through dynamic regulation of a set of choles-
terol synthesis genes relevant for patient survival.
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In order for tumor cells to form metastases, they ﬁrst have toacquire an invasive potential, which allows the cells to emi-grate from the primary tumor, to reach the blood stream, and
eventually to colonize distant organs, where they can build sec-
ondary tumors. In many solid cancers, acquisition of the invasive
behavior is due in part to a process called epithelial-
mesenchymal-transition (EMT)1. In melanoma a very similar
phenomenon, i.e., the dynamic and reversible transition from a
proliferative to an invasive state, has also been described and is
known as “phenotype switching”2–4. As for EMT in other solid
tumors, induction of ZEB, TWIST, and SNAIL transcription
factor family members, as well as repression of the cell adhesion
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molecule E-cadherin (CDH1), are important for melanoma pro-
gression5. However, in melanoma only ZEB1 and TWIST1 seem
to be implicated in disease progression and metastasis, while
ZEB2 expression is to the contrary lost during these processes6.
Another crucial player in phenotype switching in melanoma is
the melanocyte-specifying microphthalmia-associated transcrip-
tion factor (MITF), which controls a variety of target genes
involved among others, in melanocyte differentiation7. High
expression of MITF deﬁnes a proliferative, non-invasive sub-
population of melanoma cells, whereas reduced levels of this
transcription factor have been associated with increased inva-
siveness and metastatic behavior8.
Melanoma cell plasticity promoted by phenotype switching
also appears to underlie the frequent development of resistance to
current therapies9. Most melanomas harbor mutations in the
mitogen-activated protein kinase (MAPK) pathway, which
represents the main oncogenic signaling pathway in melanoma.
In particular, genetic alterations in BRAF and NRAS are most
prevalent10, and substantial efforts have been made in the clinics
to develop selective inhibitors of the MAPK pathway. This has led
to major advances in the treatment of patients with melanoma,
resulting in improved overall survival rate11. Unfortunately,
relapses occur in the majority of cases, indicating that some cells
in the tumor mass are resistant or develop resistance to thera-
pies12. Mechanistically, this has been linked to acquisition of an
expression proﬁle reminiscent of de-differentiated melanocytes13.
In particular, high expression of MITF in melanoma cells confers
high sensitivity to MAPK pathway inhibition, while MITFlow cells
are intrinsically more resistant to those treatments13,14. These
states appear to be regulated by ZEB1: At least in some melanoma
cell lines, ZEB1 overexpression induces resistance to BRAF/MEK
inhibitors associated with a conversion of a MITFhigh into a
MITFlow phenotype and with high expression of the nerve growth
factor receptor CD271 (also termed NGFR, p75NTR) in resistant
cells15,16. Likewise, recently established immunotherapies pro-
mote intrinsic changes in melanoma cells associated with tumor
cell de-differentiation and resistance formation17. In this case,
therapy-induced proinﬂammatory cytokines like TNFα trigger
emergence of amelanotic tumors expressing high levels of
CD2719. Establishment of resistance and overall increased CD271
expression appears to involve cellular reprogramming, as cells
expressing CD271 along with other resistance markers are rare in
pre-treated melanoma cell lines and patient-derived xenografts16.
Although controversial18, CD271 was identiﬁed before as a
marker for melanoma-initiating cells, and high CD271 expression
in patients was shown to correlate with increased metastasis and
poor prognosis19,20. Intriguingly, CD271 inactivation not only
resulted in decreased melanoma cell survival, but also in
increased sensitivity to BRAF inhibitor treatment, suggesting that
CD271 confers therapy resistance21. However, the function of
CD271 in phenotype switching remains to be determined.
In this study, we show that CD271 is a crucial molecule in the
control of melanoma cell growth vs. invasiveness. Temporal
overexpression of CD271 leads to reduced proliferation and
adhesion in vitro and to increased metastasis formation in vivo.
Mechanistically, we found the CD271 intracellular domain (ICD)
to regulate proliferation, while the interaction of CD271 with
Trk-A mediates adhesion via regulating a group of cholesterol
biosynthesis genes.
Results
CD271high expression is linked to an invasive signature. To
characterize CD271-expressing melanoma cells in vivo, we ﬁrst
determined the genetic signature of this subpopulation of cells at
the time of invasion. To do so, we used an orthotopic in vivo
model established in our laboratory that is able to recapitulate
early events in melanoma progression, including the break out of
cells from the primary tumor22. More precisely we seeded human
melanoma cells stably expressing GFP into engineered human
skin substitutes that were transplanted onto the back of immu-
nocompromised rats (Fig. 1a). Within 6 weeks, human melanoma
cells started to move from the epidermis to the dermis of the
reconstituted skin, simulating an invasion process (Fig. 1b). At
this time point, we dissociated the transplant and human mela-
noma cells were isolated based on GFP expression and separated
by FACS into two populations, expressing high (CD271high) and
low levels of CD271 (CD271low) respectively (Fig. 1c). Gene
expression (Affymetrix) (Fig. 1d) and MetaCoreTM analysis of
these two populations revealed that the CD271high population,
compared with the CD271low one, was enriched for processes like
cell cycle, epithelial to mesenchymal transition (EMT), extra-
cellular matrix remodeling and adhesion, and upregulation of
MITF in melanoma (Fig. 1e). Figure 1f shows selected genes from
MetaCoreTM pathways with most signiﬁcant differential expres-
sion. These data are consistent with a role of CD271high cells in
proliferation and invasion.
According to the phenotype switching model3, melanoma cells
becoming invasive slow down proliferation and decrease the
expression of differentiation markers. Therefore, we used TCGA
data (http://cancergenome.nih.gov/) to compare CD271 expres-
sion levels with melanocytic differentiation and invasion markers
(Fig. 1g–p). This analysis showed a signiﬁcant inverse correlation
of CD271 expression with MITF, Tyrosinase, MLANA, PMEL,
and CDH1 and a positive correlation with ZEB1, TWIST1,
WNT5A, c-JUN, and AXL, strengthening the association of
CD271 expression with an invasive phenotype23,24.
To assess a potential involvement of CD271 in melanoma
formation, we ﬁrst made use of human melanoma cell lines with
different intrinsic CD271 expression levels. CD271 protein is
expressed rarely in a tumor bulk20,25 and consequently only few
human melanoma cell lines derived from tumors express high
levels of the protein, as revealed by Western blot analysis
(Supplementary Fig. 1a). To assess the growth of cells with
different CD271 levels, we injected two cell lines (CD271low and
CD271high, M010817 and M050829, respectively) into immuno-
compromised mice. To follow their growth in vivo, the cells had
Fig. 1 CD271 correlates with an invasive signature and decreased proliferation. a Scheme illustrating the experimental approach using human organotypic
skin substitutes as the basis for a humanized in vivo melanoma model to study melanoma invasion. Human melanoma cells (M070413) stably expressing
GFP are mixed with human keratinocytes (HKC) and seeded onto high-density type-I collagen hydrogels containing human dermal ﬁbroblasts (HFB). This
human dermo–epidermal skin equivalent is then transplanted onto immunocompromised rats. b Immunoﬂuorescent staining of GFP and CD271 on sections
of transplanted human organotypic skin substitutes (M Melanoma, D Dermis). Scale bar 75 µm. c After excision, cells were isolated from the skin
equivalent and sorted for GFP and CD271 high and low populations. d Gene expression analysis of the CD271 high and low populations (n= 2, Log2 ratio<
−0.6,> 0.6; FDR< 0.5). e Pathway analysis of the CD271 high vs. low population with MetaCoreTM (http://thomsonreuters.com/en.html). f Selected
genes with highest signiﬁcance from the MetaCoreTM analysis representing enrichment of the EMT, Cell Adhesion, ECM Remodeling, Cell Cycle,
Upregulation of MITF in melanoma and other pathways. g–p Correlation of RNA seq. data from TCGA for CD271 with MITF, Tyrosinase (TYR), Melan-A
(MLANA), PMEL, E-cadherin (CDH1), ZEB1, TWIST1, WNT5A, c-JUN, and AXL genes
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been stably transformed with a lentivirus carrying infrared
ﬂuorescent protein (iRFP), allowing assessment of tumor growth
by an In Vivo Imaging System (IVIS)25 (Fig. 2a). Cells expressing
low levels of CD271 were fast growing and formed a 1 cm3 tumor
in less than four weeks. On the contrary, the cells expressing high
levels of CD271 were slow growing and formed a small tumor in
the same period of time (Fig. 2a, b). Histological analysis and
immunohistochemical staining for CD271 conﬁrmed the differ-
ent size of tumors generated by cells expressing either low or high
levels of CD271 in vivo (Fig. 2c). These results indicate that a cell
line endogenously overexpressing CD271 protein proliferates
slowly as compared to a cell line expressing basal levels of the
protein.
Given the correlation between CD271 expression, proliferation,
and invasion marker expression, we next investigated whether
CD271 levels are altered in cells undergoing a transition from
proliferation to invasiveness. TGFβ is known to slow down cell
cycle progression and to induce an EMT-like process and
invasiveness in melanoma cells2,26. Treatment of CD271low
melanoma cell lines with TGFβ1 at different time points led to
an increase in CD271 expression at both messenger RNA
(mRNA) and protein levels in different cell lines (Fig. 2d, e and
Supplementary Fig. 1b). As expected, other mesenchymal
markers, including Fibronectin (FN) and N-cadherin (CDH2),
were also upregulated. Similarly, an increase in CD271 protein
levels was observed by knocking down the epithelial marker
CDH1 either transiently by siRNA or stably by shRNA
(Supplementary Fig. 1c). These results indicate that CD271 is
induced when an EMT-like cascade is triggered in melanoma, in
agreement with recent studies revealing high CD271 expression
upon ZEB1 overexpression15. Taken together, our data are
consistent with the idea that CD271 levels are involved in
melanoma cell proliferation and invasion.
CD271 overexpression counteracts proliferation and adhesion.
To assess whether reduced proliferation was due to an intrinsic
CD271 function, we stably overexpressed this factor in a
CD271low melanoma cell line, using a lentiviral backbone also
carrying red ﬂuorescent protein (RFP) and infrared ﬂuorescent
protein (iRFP) as markers (Fig. 3a). After 72 h of infection,
CD271-overexpressing cells incorporated signiﬁcantly less EdU in
percentage, as compared with control cells (Fig. 3b). Moreover,
when injecting CD271-overexpressing cells into immunocom-
promised mice, tumor growth was impaired as compared to
control cells (Fig. 3c, d). Furthermore, cells overexpressing CD271
acquired a roundish morphology and eventually detached from
the plate (Fig. 3e). Indeed, if transferred to adhesion-favorable
ﬁbronectin-coated plates, CD271-overexpressing cells were able
to re-attach, demonstrating a CD271-induced adhesion pheno-
type in melanoma cells (Fig. 3f). The cells in suspension were
collected and counted (Fig. 3g) and shown to represent the cell
fraction with the highest CD271 expression levels, both at mRNA
and protein levels (Fig. 3h, i). Although the number of cells in
suspension that re-attached on ﬁbronectin-coated plates was
higher in the CD271 overexpressing cohort than the number of
re-attached control cells (Fig. 3f), they were outgrown by control
cells after 10 days in culture, further conﬁrming the growth
impairment of cells overexpressing CD271 (Fig. 3j). Taken
together, these data show that forced expression of CD271
impairs proliferation and adhesion, consistent with an invasive
phenotype of CD271high cells.
Transient CD271 overexpression promotes metastasis forma-
tion. On the basis of our ﬁndings we hypothesized that in pri-
mary tumors CD271 needs to be up-regulated in order to
promote a phenotype switch from a proliferative to a less pro-
liferative, more invasive phenotype and to be downregulated
again in order to allow tumor re-growth and, hence, establish-
ment of metastases in secondary organs. To investigate the
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proposed mechanism, we engineered a TetON lentiviral expres-
sion system25, based on the T-RExTM system, to transiently
overexpress CD271 in melanoma cells (Fig. 4a, Supplementary
Fig. 2a). With this vector system (termed CMVTOCD271), we
were able to overexpress CD271 in melanoma cells by doxycy-
cline treatment and revert its expression to basal levels by sub-
sequently removing the compound (Supplementary Fig. 2b–d,
Supplementary Fig. 3a). Similar to the results obtained by means
of stable overexpression, continuous CD271 expression in this
system impaired growth in vitro and in vivo (Supplementary
Fig. 2e–h, Supplementary Fig. 3b, c and h) and adhesion in vitro
(Supplementary Fig. 2i, Supplementary Fig. 3d–g). To study the
effect of dynamic CD271 expression on melanoma cell growth
and adhesion, we transiently induced CD271 expression by short-
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term doxycycline administration. As shown by crystal violet
staining, doxycycline treatment for 1 day impaired growth of cells
adherent to uncoated culture dishes (Fig. 4b) and increased the
number of cells in suspension (visualized by replating on
ﬁbronectin-coated culture dishes; Fig. 4b). After removal of
doxycycline, the cells regained their growth capacity, observed as
a drastic increase in the number of cells both in the adherent and
suspension fraction (Fig. 4b, c). Thus, sequential “off-on-off”
expression of CD271 impairs proliferation and adhesion of cul-
tured melanoma cells in a reversible manner.
Our ﬁndings suggest that transient CD271 overexpression
promotes reversible phenotype switching in melanoma cells. To
examine the consequences of dynamic CD271 expression in vivo,
we injected cells carrying the inducible CMVTOCD271 expres-
sion construct and control cells (carrying a vector termed
CMVTOEV) into immunocompromised mice. After injection,
tumors were allowed to grow for 1 week before systemic
doxycycline administration in drinking water for an additional
week. Subsequently, the mice were released from doxycycline for
2 further weeks (Fig. 5a). As expected, the tumors initially grew in
both CMVTOEV and CMVTOCD271 xenografts (Fig. 5b, c, and
Supplementary Fig. 3h). After doxycycline administration, the
CMVTOCD271 tumors slowed down their growth, while the
control tumors continued to grow progressively. Importantly, the
CMVTOCD271 tumors started to grow again after release from
doxycycline.
Our cell culture data demonstrated decreased adhesion
properties of cells overexpressing CD271, which possibly might
result in an increased metastatic potential in vivo. Accordingly,
reversible “off-on-off” expression of CD271 would allow
melanoma cells to grow at the primary injection site, to leave
the primary tumor upon doxycycline-mediated CD271 over-
expression, and to regain growth capacity and to form metastases
at distant sites upon doxycycline release and reduction of CD271
levels. To test this hypothesis, we collected the lungs from mice
that were injected either with CMVTOEV or
CMVTOCD271 cells and transiently treated with doxycycline.
The presence of metastatic cells in the lung was monitored by
qRT-PCR for GFP (expressed from the lentiviral backbone,
Fig. 4a). As shown in Fig. 5d and Supplementary Fig. 4, lungs
from animals, in which CD271 had been transiently over-
expressed, exhibited signiﬁcantly increased GFP mRNA levels as
compared with controls. Likewise, the lungs of such mice
presented a high load of macroscopically visible GFP-positive
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coated plates (lower panels). Not treated (day 0), treated with doxycycline for 24 h (day 1), and subsequently released from doxycycline for 48 h (day 4). c
Quantiﬁcation of cell numbers of b (n= 3, P values> 0.05,≤ 0.01). Error bars indicate S.D. All experiments done with cell line M010817
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metastases (Fig. 5e). In contrast, constant CD271 overexpression,
starting with doxycycline administration one week after cell
injection (Fig. 5f), slowed down melanoma cell proliferation
in vivo (Fig. 5g, h), as expected, but did not alter the amount of
GFP-expressing cells in the lungs when compared to the lungs of
control mice (Fig. 5i). These data demonstrate that a switch in
CD271 expression promotes melanoma metastasis formation in
distant organs.
Different signaling axes regulate proliferation and adhesion.
CD271 is a single-pass transmembrane receptor that belongs to
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Fig. 5 Transient CD271 overexpression in vivo increases metastasis. a Time course for the transient CD271 expression experiment in vivo. At day 0 (d0)
the mice were injected with melanoma cells carrying CMVTOEV or CMVTOCD271 vectors. 1 week after injection (d7), the mice were treated with 200
ng/ml of doxycycline for 1 week until day 14 (d14). The mice were then released from doxycycline and analyzed 2 weeks later (d28). Different
measurements (m1, m2, m3, m4) were done by IVIS to check tumor growth at different time points. b In vivo imaging of Nude mice injected with cells
carrying CMVTOEV or CMVTOCD271 vectors. m1= start of doxycycline treatment; m2= during doxycycline treatment; m3= end of doxycycline
treatment; m4= 2 weeks after release of doxycycline. c Quantiﬁcation of the IVIS signal for infrared protein (iRFP) (4 mice for a total of 8 injections were
analyzed for both conditions; P value_m1> 0.05, P value_m2≤ 0.05, P value_m3≤ 0.05, P value_m4> 0.05). Error bars indicate S.E.M. d qRT-PCR for GFP
transcripts in lung lysates of Nude mice treated according to a (n= 6 for each condition. P value≤ 0.05). Error bars indicate S.E.M. e Representative
pictures of lungs at the end of the experiments to detect GFP. To enhance the visibility of the GFP spots, the pictures were set to grayscale and inverted. f
Time course for the control experiment, in which CD271 expression was not switched. The experiment was designed as in a with the exception that
between day 7 (d7) and day 28 (d28) the mice were not released from doxycycline but continuously treated. g In vivo imaging of Nude mice injected with
cells carrying CMVTOEV or CMVTOCD271 vectors at different time points of the experiment (m1= Start of doxycycline treatment; m2=During
doxycycline treatment; m3=During doxycycline treatment). h Quantiﬁcation of the IVIS signal for iRFP (4 mice for a total of 8 injections were analyzed for
both conditions; P value_m1> 0.05, P value_m2≤ 0.05, P value_m3≤ 0.001). Error bars indicate S.E.M. i qRT-PCR for GFP transcripts on lung lysates of
Nude mice treated according to f. (n= 4 for each condition P value> 0.05). Error bars indicate S.E.M. All experiments done with cell line M010817
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the Trk receptor family. It comprises an extracellular domain able
to interact with speciﬁc ligands (neurotrophins) and an intra-
cellular domain (ICD) that is released into the cytoplasm upon
cleavage by metalloproteases27. The proteolytic processing of
CD271 involves, ﬁrst, the release of a membrane-bound carbox-
iterminal fragment, followed by γ-secretase-mediated cleavage,
which generates a soluble ICD with signaling capabilities28. ICD
is important for CD271-mediated control of neuronal survival
and the control of neurite outgrowth29, but is also involved in
apoptotic signaling30. The role of ICD in cancer is still under
investigation. In glioma, it has been associated with invasion31,
but its role in melanoma has not been addressed so far. To study
whether ICD mediates the above-described effects of CD271 in
melanoma, we cloned this part of the CD271 receptor into a
lentiviral backbone and overexpressed it in melanoma cell lines
(Fig. 6a). Upon ICD overexpression cells reduced proliferation
both in vitro and in vivo (Fig. 6b–d), while cellular adhesion was
not affected (Fig. 6e–g). Consequently, the number of adherent
cells upon ICD overexpression was lower than in the control,
while the number of cells in suspension was not changed, unlike
upon full-length CD271 expression.
CD271 binds neurotrophins with low afﬁnity via its extra-
cellular domain. By heterodimerization with other Trk receptors,
its binding afﬁnity for neurotrophins is increased. Speciﬁcally,
CD271 binds NGF with Trk-A, BDNF with Trk-B and NTF-3
with Trk-C. All of these neurotrophins and their high afﬁnity
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receptors are expressed by melanoma cells, suggesting autocrine
signal activation32. It has been shown that NGF is able to induce
invasion in melanoma cell lines and that this is dependent on the
presence of CD27132,33. Furthermore, among all neurotrophins,
only NGF is associated with poor prognosis when expressed at
high levels in melanoma specimens, as revealed by TCGA data
analysis (Supplementary Fig. 5). Therefore, we hypothesized that
NGF/Trk-A in conjunction with CD271 could be involved in the
cellular phenotypes seen upon CD271 overexpression. To test this
idea, we overexpressed CD271 through the TetON system and at
the same time knocked down Trk-A by siRNA transfection.
Notably, the defect in proliferation observed upon CD271
overexpression was not rescued by Trk-A inactivation, indicating
that CD271-dependent proliferation does not involve its interac-
tion with Trk-A (Fig. 6h). In contrast, loss of adhesion induced by
CD271 overexpression was signiﬁcantly reverted upon simulta-
neous Trk-A knock down (Fig. 6i, j). Taken together, the data
suggest that the two main consequences of CD271 overexpres-
sion, loss of adhesion and reduced proliferation, are mediated
through two different CD271 signaling axes. While the interac-
tion of CD271 with Trk-A is responsible for the loss of adhesion,
the release of ICD is crucial for the anti-proliferative effect of
CD271.
Changes in adhesion involve cholesterol synthesis. To address
the mechanisms by which reversible “off-on-off” expression of
CD271 might inﬂuence the dynamic behavior of melanoma cells,
we performed RNA sequencing (RNAseq) of
CMVTOCD271 cells before, during and after transient CD271
overexpression. Differentially expressed genes were clustered by
considering for a ﬁrst group genes signiﬁcantly upregulated
during transient CD271 overexpression followed by signiﬁcant
downregulation and, vice versa for a second set of genes, by
identifying genes signiﬁcantly downregulated during transient
CD271 overexpression with subsequent signiﬁcant upregulation
(Fig. 7a). Genes with such dynamic expression patterns were
termed “switching” genes and consisted of 160 genes being up-
and 303 genes downregulated in a reversible manner upon short-
term CD271 expression. Intriguingly, gene ontology enrichment
analysis revealed that dynamic short-term CD271 overexpression
regulates processes such as lipid and cholesterol biosynthesis and
metabolism, rather than EMT or other well-established inva-
siveness programs (Fig. 7b). In particular, we found only little
overlap, with inconsistent up- or downregulation, between
CD271-dependent transcriptional changes and signatures pre-
viously reported to characterize proliferative vs. invasive pro-
grams in established human melanoma cell lines by Hoek et al.
and Verfaillie et al.3,34 (Supplementary Fig. 6a–d). The
transcriptional cell states deﬁning proliferative and invasive cells,
respectively, have been associated with variable expression of
MITF and the receptor tyrosine kinase AXL24. Moreover, speciﬁc
gene expression programs were identiﬁed that distinguish AXL-
high/MITFlow and AXLlow/MITFhigh cells35. However, only 2–5%
of the genes controlled by short-term CD271 overexpression
represented genes of the published MITF or AXL programs
(Supplementary Fig. 6e and f) and Gene Set Enrichment Analysis
did not detect a signiﬁcant correlation or anticorrelation between
the datasets (Supplementary Fig. 6g and h). Furthermore, CD271
overexpression did not appear to inﬂuence MITF expression in
tumors in vivo (Supplementary Fig. 7). Thus, short-term transient
CD271 might inﬂuence processes that are either independent of
previously reported invasive transcriptional programs or not
represented in these programs because the latter likely reﬂect
established states rather than transient states of cells undergoing
phenotype switching.
Previous studies have reported a positive association between
elevated cholesterol levels and increased cancer risk, disease
progression, and metastasis formation36,37. Moreover, increased
activity of the cholesterol pathway correlates with decreased
survival of melanoma patients38. As shown in Fig. 7c, transient
CD271 overexpression led to reversible upregulation of a set of
genes crucial for cholesterol and lipid biosynthesis, many of
which have been linked to cancer progression38. Importantly, we
found that high expression of some of those key enzymes
regulated by CD271 is associated with worse melanoma patient
survival in TCGA (Fig. 7d). In contrast, genes annotated to cell
cycle regulation were transiently downregulated during CD271-
dependent phenotype switching (Fig. 7e). Of note, ICD expres-
sion in melanoma cells led to signiﬁcant downregulation of most
of these cell cycle regulator genes (Fig. 7f), in agreement with the
anti-proliferative role of ICD described above. In contrast, ICD
did not inﬂuence the expression of selected cholesterol synthesis
genes (Fig. 7g). To rule out any putative effect of doxycycline on
the mentioned gene sets, expression levels of CD271-controlled
cell cycle regulator and cholesterol and fatty acid biosynthesis
genes were measured by qRT-PCR on control cells (M010817
CMVTOEV) treated with either vehicle or doxycycline, however
expression of those genes was not affected by doxycycline
(Supplementary Fig. 8).
Given the suggested role of cholesterol synthesis in metastatis
formation38 and the above-mentioned CD271/Trk-A-mediated
alterations in tumor cell adhesion, we next asked whether control
of cholesterol synthesis by CD271 is Trk-A dependent. Strikingly,
in all cases tested, the CD271-induced upregulation of cholesterol
synthesis genes was reverted upon Trk-A knock down (Fig. 8a–i).
Fig. 6 CD271 regulates proliferation and adhesion via separate signaling axes. a Representation of the lentiviral vector for stable overexpression of the Intra
Cellular Domain (ICD) of CD271. The viral backbone contains Green Fluorescent Protein (GFP) and infrared ﬂuorescent protein (iRFP) reporters under the
SV40 and PGK promoters respectively, as well as the ICD overexpression cassette (ICD OE) or an empty vector (EV) under the CMV promoter. b FACS
analysis for EdU incorporation in cells overexpressing ICD (ICD OE) compared to control cells (EV) (n= 3; P value≤ 0.05). c In vivo imaging of Nude mice
injected with cells carrying the empty vector (EV) or the ICD overexpressing vector (ICD OE). The signal is from the iRFP present in the lentiviral backbone.
d Quantiﬁcation of the signal obtained by IVIS for iRFP (three mice for a total of six injections were analyzed for each conditions; P value_m1≤ 0.05, P
value_m2≤ 0.05). Error bars indicate S.E.M. e Brightﬁeld (upper panel) and ﬂuorescent micrographs (lower panel) of melanoma cells in culture 72 h after
infection with the EV or ICD OE vector. Scale bars 100 µm. f Crystal violet staining of adherent cells (upper panel) and suspension cells, after re-attachment
on ﬁbronectin-coated plates (lower panel), carrying either the control vector (EV) or the ICD overexpressing vector (ICD OE). g Quantiﬁcation of adherent
and suspension cells after infection with EV or ICD OE constructs (n= 3, P value_adh.cells≤ 0.05, P value_susp.cells> 0.05). Error bars indicate S.D. h
FACS analysis for EdU incorporation in cells infected with CMVTOEV or CMVTOCD271 constructs and transfected with sicontrol or siTrk-A. One day after
siRNA transfection the cells were treated with doxycycline (1 μg/ml) for 24 h. Cells were then pulsed with EdU for 30min and collected for FACS analysis
(n= 3; P value≤ 0.05). i Crystal violet staining of suspension cells (forced to reattach on ﬁbronectin-coated plates) infected with CMVTOEV or
CMVTOCD271 and transfected with siControl (upper panel) or siTrk-A (lower panel). The cells were treated, as described in h. j Quantiﬁcation of
suspension cells (CMVTOEV or CMVTOCD271 infected) after siRNA transfection and doxycycline administration (as described in h) (n= 3, P value≤
0.05, P value≤ 0.001). Error bars indicate S.D. All experiments done with cell line M010817
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01573-6 ARTICLE
NATURE COMMUNICATIONS |8:  1988 |DOI: 10.1038/s41467-017-01573-6 |www.nature.com/naturecommunications 9
Our data are consistent with the hypothesis, that elevated
cholesterol synthesis is implicated in CD271/Trk-A-mediated
changes in cell adhesion. To test this idea, we treated CMVTOEV
and CMVTOCD271 cells with doxycycline and measured
CD271-induced cell detachment in the presence or absence of
either Lovastatin or MF-438, two established inhibitors of
cholesterol synthesis39,40. While in the control settings
(CMVTOEV), addition of cholesterol synthesis inhibitors did
not elicit any overt effects on cell detachment, treatment with
both Lovastatin and MF-438 rescued the loss of cell adhesion
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induced by CD271 overexpression (Fig. 8j, k). Thus, CD271/Trk-
A appears to increase cholesterol synthesis levels, which is
functionally implicated in modifying adhesion properties of
melanoma cells.
Discussion
The capacity of melanoma cells to dynamically switch between
proliferative and invasive phenotypes is thought to underlie
tumor progression, metastasis formation and therapy resistance
in melanoma4. In the present study, we identify the low afﬁnity
neurotrophin receptor CD271 to play a dual role as a mediator of
phenotype switching, suppressing melanoma cell proliferation
while concomitantly promoting metastasis formation in vivo.
CD271 is one of several molecules that have been implicated in
the decision of “growing vs. going” in melanoma cells14,41,42.
Among the best-studied pathways involved in melanoma cell
plasticity is Wnt signaling, which has a canonical signaling
branch acting through β-Catenin and a non-canonical branch
able to suppress canonical signaling43. In melanoma, canonical
Wnt promotes high MITF expression and tumor growth44,45,
whereas non-canonical signaling by Wnt5a and reduced MITF
expression promote an invasive phenotype23. However, although
TCGA data analysis revealed an inverse correlation between
CD271 and MITF in human melanoma samples, we did not ﬁnd
evidence for a direct link between Wnt signaling, MITF regula-
tion, and CD271. In particular, CD271 overexpression did not
prevent MITF expression in human melanoma cells in vivo.
Furthermore, reversible CD271 overexpression controlled a gene
expression program hardly overlapping with previously estab-
lished gene expression signatures deﬁning proliferative vs. inva-
sive cells3,34,35. Possibly, phenotype switching in melanoma
involves distinct pathways able to control proliferation vs. inva-
siveness by independent mechanisms, although this needs to be
further addressed in future work. In fact, phenotype switching in
melanoma can be induced by many different stimuli, including
hypoxia, therapies targeting the MAPK pathway, and immu-
notherapies4,17,43,46. Alternatively, however, the gene sets that we
show to be dynamically controlled by reversible CD271 expres-
sion may characterize a state of a cell captured in the process of
phenotype switching; most likely, such a state was simply not
present or at least underrepresented in the long-term cell cultures
from which proliferative and invasive programs were estab-
lished3,34. This could also explain why CD271 expression itself is
also not part of those published invasiveness gene expression data
sets. Furthermore, cells just undergoing CD271-mediated phe-
notype switching are conceivably rare in the tumor bulk16, which
could account for the very limited overlap between the CD271-
controlled gene expression program and the MITF and AXL
programs derived from human patient biopsies35. In contrast,
CD271 itself is part of the MITFlow/AXLhigh program derived
from single cell analysis of melanoma tissue in vivo35, consistent
with our ﬁnding that CD271 appears to be expressed in invasive
cells in reconstituted skin in vivo. Possibly, the program down-
stream of CD271 might become attenuated with time in AXLhigh
cells. Furthermore, in vivo, not all CD271/AXLhigh cells are
presumably exposed to NGF or other ligands stimulating the
CD271 signaling axis.
On the basis of our ﬁndings, CD271 appears to exert its two
functions in phenotype switching through distinct modalities:
First, heterodimerization of CD271 with the Trk-A receptor,
which mediates NGF signaling, speciﬁcally affects melanoma cell
invasiveness, but not proliferation. Second, ICD resulting from
CD271 processing suppresses proliferation without altering
adhesion and invasiveness of melanoma cells. Accordingly,
inactivation of Trk-A prevented CD271 from inducing loss of
adhesion, while expression of ICD in melanoma cells phe-
nocopied the effect of CD271 on proliferation but not on inva-
siveness. Expression analysis of genes dynamically controlled by
CD271 in an experimental set-up mimicking reversible pheno-
type switching revealed a set of cell cycle regulator genes that are
downregulated by ICD. Although the exact mode of action of
ICD in melanoma has not been investigated, the data are com-
patible with ICD counteracting proliferation. Likewise, genes
involved in cholesterol synthesis were also dynamically controlled
during phenotype switching. However, these genes turned out to
be targets of Trk-A-mediated CD271 signaling and not controlled
by ICD. Deregulation of cholesterol biosynthesis has been asso-
ciated with several cancer types47,48. In melanoma, around 60% of
all patients display increased expression of or copy number gains
in cholesterol synthesis genes and, according to the TCGA
database, high expression of a gene signature representing the
activity of the cholesterol synthesis pathway correlates with
decreased melanoma patient survival38. Cholesterol is a precursor
for steroid hormones and plasma membrane components and, in
addition, plays a role in intracellular signal transduction38.
However, it remains elusive how changes in cholesterol synthesis
affect tumor progression. Increases in intracellular cholesterol
levels have been reported to promote tumor angiogenesis49,
survival of mesenchymal cancer cells, cancer cell migration50,
EMT51, and metastasis formation38,50,52. In melanoma, high
doses of statins—which efﬁciently block cholesterol synthesis—
were reported to inﬂuence, among others, cell migration and
invasion53,54 and to reduce metastasis formation by murine B16
melanoma cells intravenously injected into syngeneic mice55.
Likewise, an anti-tumorigenic and anti-metastatic effects of sta-
tins was also demonstrated for cancer types other than mela-
noma56–58. In agreement with these studies, we found inhibitors
of cholesterol synthesis to counteract CD271/Trk-A-dependent
dissemination of melanoma cells. These ﬁndings raise the intri-
guing question of whether changes in cholesterol and, possibly,
lipid metabolism59 are involved in melanoma phenotype
switching.
Fig. 7 Transcriptome analysis upon transient CD271 overexpression. a RNAseq of cells before, during and after CD271 transient overexpression was
performed and analyzed using edgeR. Genes were ﬁltered for Log2≥ +0.27 and ≤−0.27, p-value< 0.05, FDR< 0.05, which resulted in 160 genes
signiﬁcantly upregulated upon CD271 overexpression (comparing CMVTOCD271 + DOX 24 h over CMVTOCD271 –DOX24 h) with subsequent signiﬁcant
downregulation (comparing CMVTOCD271 + DOX 24 h/−DOX 48 h over CMVTOCD271 + DOX 24 h) and vice versa in 303 genes signiﬁcantly
downregulated upon CD271 overexpression with subsequent signiﬁcant upregulation. Heatmap represents row z-scores of normalized counts from
RNAseq. b Top 20 gene ontology process enrichments from MetaCoreTM. Numbers in brackets indicate the number of differentially expressed genes
above the total number of genes within an annotated pathway. c Selected “switching” genes from a involved in cholesterol and lipid biosynthesis pathways.
Again, heatmap represents row z-scores of normalized counts from RNA Seq. d Survival curves based on TCGA data for expression of cholesterol
biosynthesis genes in human melanoma samples. Data from 114 patients per condition were analyzed, which represent 25% of highest and lowest
expressing patients. e Selected “switching” genes from a involved in cell cycle regulation. Again, heatmap represents row z-scores of normalized counts
from RNA Seq. f qRT-PCR for cell cycle genes in ICD overexpressing and EV melanoma cells. g qRT-PCR for cholesterol and lipid biosynthesis genes in ICD
overexpressing and EV melanoma cells. For f and g, n= 3 for each condition. P values> 0.05= n.s., P values≤ 0.05= *, P values≤ 0.01= **, P values≤
0.001= ***. Error bars for f and g indicate S.D. All experiments done with cell line M010817
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Our data are in line with previous studies reporting a role of
NGF and/or CD271 in mediating melanoma cell invasion in vitro
and of neurotrophins and their receptors in promoting melanoma
cell migration32,33,60. However, there are also discrepancies
between our work and other studies. For instance, it has been
suggested based on siRNA-mediated knock down assays that
signaling through Trk/CD271 receptor complexes, while pro-
moting invasiveness, also stimulates melanoma cell prolifera-
tion32. Moreover, according to another study, CD271
overexpression decreased melanoma cell proliferation, as well as
invasiveness61. Likewise, ICD has been implicated in glioma
invasiveness27, whereas we found it to affect proliferation in
melanoma cells, but not invasiveness. The use of different assays
for invasiveness, migration, and adhesion or of different cell lines
and cell types might partially explain these discrepancies. Fur-
thermore, the biological activity of CD271 appears to be highly
dependent on its expression levels. As shown in our study, high
expression of the protein leads to low proliferation and increased
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invasion, while expression at basal levels deﬁnes a highly pro-
liferative, but non-invasive state. However, we and others
observed that CD271 stable knock down leading to its complete
inactivation fully abolishes growth of melanoma cells21,62.
Therefore, we advocate that a role of CD271 in phenotype
switching can best be assessed by dynamically modulating its
expression in vivo, as it is thought to occur in melanoma cells
adopting a metastatic phenotype or in response to therapies.
Indeed, constitutive expression of CD271 did not increase
metastasis formation in our study, as well as in a recent report
using zebraﬁsh as model system61. Therefore, high CD271 levels
have to revert to basal levels in metastatic cells in order for them
to re-grow at distant sites and to form secondary tumors.
It has been suggested that the cellular heterogeneity of mela-
noma is established by melanoma cell plasticity4,35. EMT and
metastasis formation, as well as therapy escape mechanisms
presumably rely on the capacity of melanoma cells to dynamically
change their phenotype in response to extracellular stimuli. This
potential is reminiscent of that of normal melanocytes, which
depending on the culture conditions are able to de-differentiate
and to adopt features of neural crest stem cells from which
melanocytes originate during embryonic development63. During
development, neural crest stem cells become highly migratory by
undergoing EMT64 and this process is associated with upregu-
lation of the transcription factor Sox10 and of CD271. Of note,
loss of Sox10 not only impairs neural crest stem cell main-
tenance65, but in melanoma also reduces the number of CD271-
positive cells and counteracts tumorigenesis66. Furthermore, in
tumors other than melanoma, the acquisition of stem cell prop-
erties has been associated with a de-differentiation process and
with EMT67. Thus, it is conceivable that CD271-positive cells
have “stem cell-like” features20,68 although this needs to be
addressed by single cell lineage-tracing experiments in vivo69.
Importantly, our data reveal that CD271 not only marks de-
differentiated melanoma cells emerging, for instance, through
TGFβ-mediated EMT, BRAF inhibitor-induced reprogram-
ming16, or in response to immunotherapies17, but also is func-
tionally involved in promoting low rates of proliferation and high
metastatic capacity. Therefore, the combined data suggest a
potential implication of CD271 in tumor relapse after therapies.
MITF induction in melanoma has been proposed as a possible
therapy for melanoma because, when elevated in cancer cells, it
triggers differentiation and sensitizes melanoma to TMECG, a
drug inducing apoptosis14. As CD271 shows a role opposite to
that of MITF, one possibility could be to treat melanoma with
drugs inducing MITF14 and at the same time blocking CD271
upregulation or function in order to prevent phenotype switch-
ing. Likewise, CD271 might be functionally implicated in drug-
induced reprogramming of melanoma cells16,21. Therefore,
although monotherapeutic use of statins does not seem to
improve survival of melanoma patients70, inhibition of CD271-
controlled cholesterol synthesis may possibly counteract mela-
noma progression and metastasis formation in combination with
other therapies.
Methods
Human organotypic skin cultures. Organotypic cultures were prepared using a
previously established transwell system consisting of 6 well cell culture inserts
containing a porous membrane (3.0 µm pore-size, BD Falcon)22. Collagen type I
hydrogels containing human dermal ﬁbroblasts were used as dermal part of the
skin substitutes. Brieﬂy, 0.7 ml rat-tail collagen type I (3.2–3.4 mg/ml, BD Bios-
ciences), was added to 0.2 ml chilled neutralization buffer containing 0.15M NaOH
and 1 × 105 ﬁbroblasts. After polymerization (10 min at room temperature and 20
min at 37 °C) these dermal equivalents were grown in DMEM supplemented with
10% FCS for 5 days. Corresponding to the physiological ratio of melanocytes to
keratinocytes (~1:5), 5 × 104 melanocytes or melanoma cells (M070413) were
mixed with 2–2.5 × 105 keratinocytes and seeded onto each dermal equivalent. To
avoid dispersion, the cells were placed into siliconized polypropylene rings of 1.5
cm diameter. After 12 h the rings were removed, 1 ml keratinocyte (Keratinocyte-
SFM, Invitrogen)/melanocyte medium (Melanocyte Growth Medium, PromoCell)
(ratio 5:1) was added in the upper chamber, and 2 ml was added to the lower
chamber. Culturing for 2 weeks with regular medium changes gave rise to the
dermo-epidermal skin substitutes used for transplantation.
Transplantation of human organotypic skin substitutes. The study was
approved by the veterinary ofﬁce of Canton of Zurich, Switzerland and was per-
formed in accordance with Swiss law. The surgical procedure was performed, as
described previously22. In short, a fully thickness skin wound was surgically created
on the back of 10 weeks old, female athymic Nu/Nu rats (Harlan, Netherlands). To
prevent wound closure from the surrounding skin, metal rings (27 mm in diameter,
made to order from stainless steel at the ETH Zurich) were sutured to the skin
using non-absorbable polyester sutures (Ethibond®, Ethicon). The dermo-
epidermal skin substitutes were placed into the rings, ﬁxed with 4–6 stitches, and
covered with a silicone foil (Silon-SES, BMS). The rings were then covered with 5 ×
5 cm2 polyurethane sponges (Ligasano®, Ligamed) and medical strip. Sedation and
anesthesia was performed as follows. Before surgery all animals were sedated with
15 mg/kg ketamine s.c. (Pﬁzer). Anesthesia was induced and maintained using
isoﬂurane (Abbott), post-operative analgesia was provided by 0.05 mg/kg bupre-
norphine s.c. (Temgesic®, Essex). Animals were killed at the indicated time point
with carbon dioxide. The grafts were excised and prepared either for immuno-
histochemical processing or FACS sorting.
Isolation of cells by FACS. The grafts were cut in small pieces and resuspended in
a solution of collagenase 3 (1 mg/ml in HBSS; ca. 10 ml per graft) for 1 h at 37 °C.
Single cells from the grafts were then diluted in complete DMEM and ﬁltered
through a cell strainer (40 uM, BD falcon). They were then centrifuged and
resuspended in complete medium plus EDTA (2 nM/l) then stained for CD271
(1:100; Miltenyi Biotec. APC-conjugated: 130-091-884; 30 min at 4 °C). Cells were
then sorted for GFP (to speciﬁcally sort melanoma cells) and for CD271 and
separated in low and high levels. For RNA extraction (for gene expression pro-
ﬁling) the cells were sorted in RTL buffer+beta-mercaptoethanol in the ratio 1:100
(Qiagen RNA minikit).
To sort melanoma cell lines after infection with viruses (carrying GFP or RFP),
we separated the cells with PBS1X containing 2 mmol/l of EDTA. The cells were
then resuspended in the same buffer and sorted then in complete RPMI (10% FCS
and 1% streptomycin/penicillin plus 5 ug/ml of gentamycin). Sorting was done
with FACSAria (BD Biosciences).
Flow Cytometry for EdU detection. Cells were pulsed with EdU (10 uM) for 30′.
Cells were then treated according to the Click-iT® EdU Flow Cytometry Assay kit
(C10425, C10424, ThermoScientiﬁc), measured with FACScanto II (BD Bios-
ciences) and analyzed with Diva software (BD Biosciences).
RNA isolation from cells and reverse transcription–qPCR. RNA extraction and
DNase treatment of samples was performed using the RNeasy Mini Kit (74104,
Qiagen) and the RNase-Free DNase Set (79254, Qiagen) according to manu-
facturer’s guidelines. Puriﬁed RNA was quantiﬁed using nanodrop and subjected to
reverse transcriptase reaction using Maxima First Strand cDNA Synthesis Kit
(K1641, Thermo Scientiﬁc) followed by an RNase H (EN0202, Thermo Scientiﬁc)
digestion step according to manufacturer’s recommendations. Real-time quanti-
tative PCR (qRT-PCR) was performed on a LightCycler 480 System (Roche) using
LightCycler 480 SYBR Green I Master (4707516001, Roche). Primers used are
indicated in Supplementary Table 1. Each sample was analyzed in technical tri-
plicates, and relative quantiﬁed RNA was normalized using β-Actin or GAPDH, as
housekeeping transcripts.
RNA isolation from lung tissue. Lungs were collected from killed mice and
immediately included in 2 ml of TRIzol® (15596026, ThermoFisher). Lungs in
TRIzol® were immediately frozen at −80 °C for one night or longer and then
homogenized with a tissue homogenizer (Polytron PT 2100, Kinematica). The
RNA from homogenized lungs was then extracted following the manufacturer’s
guidelines. After extraction, 50 μg of RNA was puriﬁed and treated with DNAse
respectively with RNeasy Mini Kit (74104, Qiagen) and the RNase-Free DNase Set
(79254, Qiagen). The reverse transcription and qRT-PCR was done, as described
before.
Microarray analysis. Total RNA was isolated as described for reverse
transcription–qPCR. Total RNA was ampliﬁed and biotin labeled using the Mes-
sageAmp II-Biotin Enhanced aRNA Ampliﬁcation Kit (AM1791, Life Technolo-
gies). Biotin-labeled RNA was hybridized to Human Gene 2.1 ST Array (902136,
Affymetrix) following the manufacturer’s protocol. After hybridization, micro-
arrays were washed and stained using a GeneChip Fluidics Station 450 (Affyme-
trix) and scanned with a GeneChip Scanner 7 G (Affymetrix). Differential gene
expression was determined by R package limma. Gene ontology network analysis
was performed with MetaCoreTM (Thomson Reuters). Microarray data have been
deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO
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Series record number GSE103382. Supplementary Data 1 contains the list of DE
genes used for MetaCoreTM analysis in Fig. 1e.
RNA sequencing. Total RNA of three experimental replicates per condition was
isolated using the RNAeasy Kit (74104, Qiagen) and RNase-Free DNase Set (79254,
Qiagen) as described in the manufacturer’s protocol. Quality control of total RNA
was done using the Agilent RNA ScreenTape assay and the Agilent 4200 TapeS-
tation. Enrichment of poly-A mRNA using magnetic beads (TruSeq RNA Library
Prep Kit v2) was done before cDNA synthesis and library preparation. Subsequent
RNA Sequencing was done with Illumina HiSeq4000 at the Functional Genomics
Center Zurich, Switzerland. RNA counts were quantiﬁed from single-end reads
using STAR aligner. Subsequent bioinformatic analysis of differentially expressed
(DE) genes was performed with EdgeR. Gene ontology network analysis was
performed with MetaCoreTM (Thomson Reuters). RNA Sequencing data have been
uploaded to the European Nucleotide Archive (ENA) and are accessible under the
study number PRJEB22305. Supplementary Data 2 contains the list of differentially
expressed genes used for MetaCoreTM analysis in Fig. 7b.
Cell cultures and reagents. Cells used for experiments were either commercially
acquired (A375) or obtained from the University Hospital Zurich where surplus
tumor material was obtained after surgical removal of melanoma metastases from
patients after written informed consent and approved by the local IRB (EK647 and
EK800). Clinical diagnosis of the tumor material was conﬁrmed by histology and
immunohistochemistry. Primary melanoma cell cultures were established from
patient biopsies using the selective adherence method (Raaijmakers et al., 2015)71
and included in the URPP biobank, University Hospital Zürich, Department of
Dermatology. Cells were grown in RPMI 1640 (Sigma Life Science, USA) sup-
plemented with 10% fetal bovine serum (Gibco, Life Technologies, USA), 2 mM
glutamine (Biochrom, Germany) and sodium pyruvate (Sigma Life Science, USA)
Work with human melanoma cells was approved by the local ethical review board
(KEK Nr. 2014-0425).
For experiments, all cells were cultured in growth RPMI 1640 medium
supplemented with 10% FCS (16140, Life Technologies), 4 mM L-Glutamine
(25030, Life Technologies) and a mix of penicillin–streptomycin antibiotics (15070,
Life Technologies).
Speciﬁc information about the cell lines used in experiments can be found in
Supplementary Table 2.
Cells carrying the inducible CMVTOEV and CMVTOCD271 constructs
respectively, were induced in vitro with doxycycline in complete RPMI 1640
medium at a concentration of 1 µg/ml for the indicated time courses. For the
detachment assay with the cholesterol inhibitors, the following ﬁnal concentrations
were used for 24 h treatment of the cells in combination with 1 µg/ml doxycycline:
Lovastatin 2.5 µM (ab120614, Abcam), MF-438 15 µM (569406, Merck Millipore).
Mice. Nude mice (Hsd:AthymicNude-Foxn1nu) were purchased from Harlan and
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, NSG) from Charles River. Mice were
housed under standard conditions with free access to water and food. Experiments
were carried out with male or female mice of 6–10 weeks of age.
For the induction of CD271 in vivo mice were treated with 2 mg/ml doxycycline
(D9891, Sigma-Aldrich) in drinking water plus sucrose (5%) for a maximal length
of 3 weeks. All experiments with animals were approved by the veterinary ofﬁce of
Canton of Zurich, Switzerland and were performed in accordance with Swiss law.
Xenografts of human melanoma cells. Melanoma cells in culture were dis-
sociated with PBS 2 mM EDTA in single-cell suspension. 300,000 cells were
resuspended in 100 μl of RPMI-1640 medium and mix 1:1 with Matrigel matrix
(356234, BD Biosciences). In total 200 μl were injected subcutaneously in both
ﬂanks of immunocompromised mice with a 1-ml syringe with a 25-gauge hypo-
dermic needle. Tumor xenografts (1 cm2) were harvested from killed mice and
prepared for histological analysis.
Histological analysis and immunoﬂuorescence. Xenograft samples were ﬁxed in
4% buffered formaldehyde and embedded in parafﬁn. The samples were processed
into sections of 4 μm thickness and slides were stained with haematoxylin and
eosin (H&E) according to standard protocols. Sections were subjected to immu-
noﬂuorescent analyses. Brieﬂy, sections were deparafﬁnized and subjected to an
antigen retrieval step using citrate buffer (S2369, Dako). Primary antibodies were
applied in blocking buffer (1% BSA in PBS and 0.05% Triton X-100) overnight at 4
°C and visualized using secondary antibodies in blocking buffer for 1 h at room
temperature. Subsequently, nuclei were stained with DAPI and slides were
mounted with Fluorescent Mounting Medium (S3023, Dako). Sections were ana-
lyzed using a DMI 6000B microscope (Leica).
Primary antibodies are listed in Supplementary Table 3. All secondary
antibodies were used at a 1:400 dilution and were purchased from Jackson
ImmunoResearch Laboratories.
MuLe cloning system. For cloning all lentiviral vectors, we used the multiple
lentiviral expression system (MuLE) that allows multiple genetic alterations to be
introduced simultaneously into mammalian cells as described in Albers et al. 25.
The CD271 full length was cloned using the following primers:
Forward: EcoRI-ATGGGGGCAGGTGCCACCGG
Reverse: EcoRI- TCACACCGGGGATGTGGCAGT
The ICD of CD271 was cloned using the following primers:
Forward: EcoRI-GTGGGCCTTGTGGCCTACATAG
Reverse: XhoI-TCACACCGGGGATGTGGCAGT
Lentivirus production. Lentiviruses were prepared using calcium phosphate-
mediated transfection of HEK293T cells cultured in DMEM plus 10% FCS and 1%
Pen/Strept antibiotics. For a 10-cm dish, lentiviral vector was co-transfected with
the lentiviral packaging vector psPAX2 (12260, Addgene) and the envelope vector
pMD2.G (12259, Addgene). After 24 h, fresh medium was added to the cells and
24 h later the supernatant containing the virus particles was collected and ﬁltered
through a 0.4 μM ﬁlter and either used directly to infect cells or stored at −80 °C for
further infections.
Lentiviral infection of human melanoma cells. Human melanoma cells were
grown at a conﬂuency of 70–80% and then incubated overnight in virus-containing
medium in the presence of 8 μg/ml polybrene (H9268, Sigma-Aldrich). After 24 h,
fresh medium was added to the cells.
In vivo imaging system. Noninvasive in vivo multispectral ﬂuorescence imaging
was performed using the In vivo imaging system (IVIS) Spectrum (PerkinElmer)
with Living Image software (version 4.4). Mice were anesthetized using 3% iso-
ﬂurane (Attane, MINRAD Inc.) in O2 at a ﬂow rate of 3–5 μl/min. The ﬁlter
channels used for calculation of tumor growth with iRFP were Ex.675/Em.725. All
measurements were performed in epiﬂuorescence mode. For the quantiﬁcation of
the total radiant efﬁciency, a region of interest was drawn around the tumor and
radiant efﬁciency was measured.
Transfection of human melanoma cells with siRNA. siRNA at a ﬁnal con-
centration of 50 nM was used to transfect cells at 50% conﬂuency. For transfection
we used the JetPrime transfection kit (114, Polyplus transfection) and we followed
the manufacturer’s guidelines. siCD271, siCDH1, and siTrk-A were all purchased
from Life Technology (Supplementary Table 4).
Protein isolation and western blotting. Cells were lysed in RIPA buffer (89900,
Thermo Scientiﬁc) containing Halt Phosphatase and Protease Inhibitor Cocktail
(78420, 87786, Thermo Scientiﬁc). Primary antibodies were applied in Odyssey
blocking buffer (927–40000, LI-COR Biosciences) overnight at 4 °C and visualized
using secondary antibodies in Odyssey blocking buffer for 45 min at room tem-
perature. Blots were scanned and quantiﬁed with an Odyssey imaging system (LI-
COR Biosciences). Quantiﬁed band intensities were normalized using either β-
Actin or γ-Tubulin as housekeeping proteins. The antibodies used for western
blotting are listed in Supplementary Table 5. Original western blots used in dif-
ferent ﬁgures can be seen in Supplementary Figure 9.
Statistical analysis. All statistical evaluations were carried out using GraphPad
Prism 5.0 and Excel. All analyses are unpaired, two-tailed Student’s t-tests. P
values≤ 0.05 were considered signiﬁcant (see below). All experiments with cell
lines were done in triplicates and error bars represent the mean± S.D. For the
in vivo imaging at least 4 injections per group were analyzed and error bars
represent the mean ± S.E.M. For the lung analysis at least three animals were used
and the error bars represent the mean± SEM. P values> 0.05= n.s., P values≤
0.05 = *, P values≤ 0.01= **, P values≤ 0.001= ***.
Data availability. The data sets generated during the current study are available in
the Gene Expression Omnibus repository (Microarray Fig. 1) under accession
number GSE103382 and in the European Nucleotide Archive (RNA Sequencing
Fig. 7) under project accession number PRJEB22305. All other remaining data are
available within the Article and Supplementary Files, or available from the authors
upon request.
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